GlaxoSmithKline has disclosed that it has so far received worldwide orders for 440 million doses of pandemic influenza A (H1N1) vaccine, an increase of 149 million doses on figures it released in August. However, other key manufacturers of pandemic H1N1 vaccines have not released aggregate figures to date.
GlaxoSmithKline has disclosed that it has so far received worldwide orders for 440 million doses of pandemic influenza A (H1N1) vaccine, an increase of 149 million doses on figures it released in August. However, other key manufacturers of pandemic H1N1 vaccines have not released aggregate figures to date.
GSK has at least 22 government orders (this does not equate to 22 countries as some have placed more than one order) and more are being discussed; in the US...
The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.
Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.
The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.
The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.
Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.
